Application of omics in the diagnosis of metabolic dysfunction-associated fatty liver disease

• Published in: Zhonghua gan zang bing za zhi Vol. 31; no. 12; p. 1245
• Main Authors: Wu, X Y, Geng, N, Chen, Q Q, Li, J
• Format: Journal Article
• Language: Chinese
• Published: China 20-12-2023
• Subjects: Gene Expression Profiling; Humans; Liver Cirrhosis; Metabolomics; Non-alcoholic Fatty Liver Disease - diagnosis; Metabolic associated fatty liver disease; Non-invasive diagnosis; Liver fibrosis; Omics
• ISSN: 1007-3418
• DOI: 10.3760/cma.j.cn501113-20230906-00094

Metabolic dysfunction-associated fatty liver disease (MAFLD) is the most common chronic liver disease worldwide, and the risk of all-cause and liver-related mortality significantly increases with the degree of fibrosis. Early diagnosis of MAFLD and its degree of liver fibrosis are of great significance, so it is particularly important to find an accurate and simple, non-invasive diagnostic method. In recent years, high-throughput omics technology has developed rapidly and played an important role in the non-invasive diagnosis and prediction of fibrosis degree in MAFLD. This article summarizes the application progress of genomics, epigenomics, transcriptomics, proteomics, metabolomics, microbiomics, radiomics, and the combination of multi-omics for the diagnosis of MAFLD disease.